SLEEKSCAPE'S 2022 CANNABIS & MARIJUANA MANIA GRAND SALAMI -- PART II

[sleekscape]

MJ-derived CBD is different than Hemp-derived CBD

Epidiolex is MJ-derived CBD

What all of the public CBD Oil companies — the hottest subsector thus far in 2018, especially since 6/25/18 when Epidiolex was FDA approved and the market knew that MJ-derived CBD would be Rescheduled within 90 days — have in common is that they smartly chose to manufacture CBD Oil from Hemp and not from MJ

The market is forward looking and has already spoken on how it feels about Hemp-derived CBD Oil stocks

Take a look at how CVSI has performed since the Epidiolex FDA approval on 6/25/18 — CVSI’s parabolic run took place in July and August, despite the fact that those summer months lie in the heart of the cannabis summer doldrums:

http://schrts.co/br5G9z


The most recent Hemp-derived CBD Oil stock to go public, CWEB, has also had an excellent launch this September:

http://schrts.co/fivVja


So when one objectively looks at how the 6/25/18 FDA approval of Epidiolex and the imminent rescheduling of MJ-derived CBD has impacted on Hemp-derived CBD Oil stocks, it is clear the the market views both as bullish catalysts

Underlying the bullish theory is that media exposure from Epidiolex rescheduling will lead to more widespread media attention on the therapeutic medical and wellness benefits of Hemp-derived CBD Oil

Media attention has always been the biggest catalyst for specific subsectors within the cannabis sector

The effect of all that media attention on CBD Oil stocks AND the massive educational campaign that the media coverage will provide, for free, to all those consumers who aren’t aware that CBD has now attained the federal government’s stamp of medical efficacy, will significantly enhance the awareness and discovery of Hemp-derived CBD oil as both a product (great for revenue growth) and an investment (great for publicly traded CBD Oil stocks)

That’s a win-win for CBD Oil companies and their shareholders


Sleek